19 completed, 13 unknown, 6 recruiting, 4 terminated. 14 Not applicable, 14 Phase 4, 10 Phase 2, 10 Phase 3, 4 Phase 1.
Follow GnRH antagonist: new trials by email Literature Review of GnRH antagonist trials Research Report on GnRH antagonist
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Purpose to Evaluate the Effectiveness of the Superovulation Stimulation Protocol Using Human Chorionic Gonadotropin (hCG) by Demonstrating Its Equivalence to Standard Controlled Ovarian Stimulation Protocols in Terms of Oocytes Retrieved, Blastulation While Maintaining an Economic Advantage Human Chorionic Gonadotropin (hCG), GnRH antagonist, Dual trigger (human chorionic gonadotropin plus GnRH-agonist) - Infertility (IVF Patients), Infertility Assisted Reproductive Technology | Not applicable | Enrolling by invitation | LTD "EKODNIPRO", Medical centre Medical Plaza Dnipro | 360 | 2026-08-17 | 2026-08-27 |
| Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A GnRH antagonist, MPA - Preimplantation Genetic Testing, Progestin-primed Ovarian Stimulation | Phase 3 | Not yet recruiting | ShangHai Ji Ai Genetics & IVF Institute | 204 | 2026-06-01 | 2026-02-02 |
| The Role of Estrogen and Testosterone in Determining Brain Blood Flow and Metabolic Regulation in Humans GnRH antagonist, Estradiol (E2), Testosterone - Cerebral Blood Flow, Cerebral Blood Flow Regulation | Not applicable | Not yet recruiting | University of British Columbia | 50 | 2026-04-01 | 2026-02-10 |
| Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer Gonadotropin Releasing Hormone Agonists and Antagonists, Bicalutamide, Biopsy Procedure - High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2025-04-16 | 2025-09-23 | |
| Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer Xaluritamig, GnRH Antagonist - Prostate Cancer | Phase 1 | Recruiting | Amgen | 40 | 2024-11-25 | 2026-07-31 |
| Comparison of Progestin Primed Ovarian Stimulation (PPOS) vs.GnRH Antagonist Methods on IVF Outcomes Progestin, GnRH antagonist - IVF, Fertility Issues | Phase 4 | Unknown | Nesta Clinic | 152 | 2024-08-01 | 2024-07-17 |
| Cardiometabolic Consequences of the Loss of Ovarian Function Degarelix, Transdermal Estradiol Patch, Transdermal Placebo Patch - Menopause, Estrogen Deficiency | Phase 4 | Recruiting | University of Colorado, Denver | 100 | 2024-06-01 | 2024-06-20 |
| Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation Progestin primed ovarian stimulation, GnRH antagonist - Infertility | Phase 2 | Recruiting | Bedaya Hospital | 120 | 2024-05-08 | 2026-05-04 |
| Late-Start Corifollitropin Alfa in Mild Ovarian Stimulation Corifollitropin Alfa 150 μg, GnRH antagonist, Progesterone - Infertile Patient Undergoing ICSI Procedure | Not applicable | Completed | Assisting Nature | 180 | 2024-01-01 | 2026-10-23 |
| Ovarian Stimulation With FSH Alone Versus FSH Plus GnRH Antagonist in an Oocyte Donor/Recipient Programme GnRH antagonist - Premature Luteinisation, Progesterone Elevation | Phase 1 / Phase 2 | Unknown | National and Kapodistrian University of Athens | 50 | 2023-04-01 | 2023-03-10 |
| Effect of GH on the Blastocyst Euploid Rate in AMA Patients Growth Hormone, GnRH antagonist - Preimplantation Genetic Testing, Growth Hormone | Phase 3 | Recruiting | ShangHai Ji Ai Genetics & IVF Institute | 400 | 2022-08-01 | 2025-02-12 |
| GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients GnRH antagonist, Letrozole 2.5mg - Endometrial Neoplasms, Atypical Endometrial Hyperplasia | Phase 2 / Phase 3 | Recruiting | Xiaojun Chen | 29 | 2022-07-13 | 2026-09-10 |
| GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients GnRH antagonist, Letrozole 2.5mg - Atypical Endometrial Hyperplasia, Progesterone Resistance | Phase 2 / Phase 3 | Active not recruiting | Xiaojun Chen | 29 | 2022-07-13 | 2025-08-11 |
| Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics (NoMEN Study) GnRH antagonist - Menopause, Estrogen Deficiency | Phase 4 | Active not recruiting | University of Colorado, Denver | 55 | 2021-11-22 | 2025-03-27 |
| Effect of GH Supplementation on the Blastocyst Euploid Rate in AMA Patients--A Retrospective Cohort Study Growth hormone, GnRH antagonist - Growth Hormone, Advanced Maternal Age | Phase 3 | Completed | ShangHai Ji Ai Genetics & IVF Institute | 692 | 2021-01-01 | 2023-02-21 |
| Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Patients Undergoing PGT-A GnRH antagonist, oral Duphaston - Preimplantation Genetic Testing, Progestin-primed Ovarian Stimulation | Phase 3 | Completed | ShangHai Ji Ai Genetics & IVF Institute | 400 | 2020-06-10 | 2025-05-31 |
| Live Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian Response Progesterone, GnRH Antagonist - IVF, GnRH Antagonist | Phase 3 | Completed | ShangHai Ji Ai Genetics & IVF Institute | 784 | 2020-06-04 | 2023-08-30 |
| Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles. GnRh antagonist, Micronized progesterone - Infertility, IVF | Not applicable | Completed | Fundacion Dexeus | 44 | 2019-09-25 | 2023-05-15 |
| Bioenergetic Effects of Aging and Menopause (BEAM) GnRH antagonist, Estrogen Product, Placebo estradiol - Menopause, Obesity, Abdominal | Phase 4 | Recruiting | University of Colorado, Denver | 57 | 2019-09-24 | 2023-12-18 |
| The Effect of ADT on PSMA Expression in Metastatic Prostate Cancer GnRH antagonist - Prostate Cancer | Not applicable | Unknown | Turku University Hospital | 35 | 2019-03-01 | 2021-04-13 |
Showing 20 of 49. Sign in to see all of them.
Infertility (11) · Obesity (4) · Polycystic Ovary Syndrome (4) · Prostatic Neoplasms (4) · Infertility, Female (3) · Endometrial Hyperplasia (2) · Ovarian Hyperstimulation Syndrome (2) · Primary Ovarian Insufficiency (2) · Progesterone Resistance (2) · Congenital Abnormalities (1) · Endometrial Neoplasms (1) · Endometriosis (1) · Endometritis (1) · Eunuchism (1) · Helping Behavior (1)
ShangHai Ji Ai Genetics & IVF Institute (5) · University of Colorado, Denver (4) · Cairo University (3) · Ferring Pharmaceuticals (2) · Massachusetts General Hospital (2) · Merck KGaA, Darmstadt, Germany (2) · Organon and Co (2) · Turku University Hospital (2) · Xiaojun Chen (2) · Amgen (1) · Assisting Nature (1) · Bedaya Hospital (1) · Bulent Haydardedeoglu (1) · Centro Ginecologia y Obstetricia. (1) · Eugonia (1)
United States (11) · China (8) · Spain (5) · Egypt (4) · Germany (3) · Finland (2) · Greece (2) · Turkey (Türkiye) (2) · Belgium (1) · Canada (1) · Iran (1) · Lebanon (1) · Taiwan (1) · Uganda (1) · Ukraine (1)
Janet E Hall, M.D. (2) · Ahmed Maged (1) · Ahmed Maged, MD (1) · Aleksander Giwercman, MD (1) · Arthur Hung (1) · Barbara Sahlin, MSc (1) · Bulent Haydardedeoglu, M.D. (1) · Daniel Bessesen, MD (1) · Ercan Bastu, M.D. (1) · George T Lainas, MD (1)
PMID 19549740, PMID 20133465, PMID 21622693, PMID 22587997, PMID 26187300, PMID 26950065, PMID 26991902, PMID 27172434, PMID 29380951, PMID 30407618, PMID 31879814, PMID 33011968, PMID 36161511, PMID 37858247, PMID 38272383, PMID 38498835, PMID 38521533, PMID 41735936, PMID 42294856, PMID 42819751
2004 (2), U54AG062319 (2), R01AG013241 (1), R01AG037603 (1), R01HL135089 (1)